Conflicting recommendations on when to screen for breast cancer are problematic for healthcare providers. The recent recommendation by the US Preventive Services Task Force (USPSTF) against routine screening…
Med Lett Drugs Ther. 2009 Dec 14; 51(1327):97-8
Conflicting recommendations on when to screen for breast cancer are problematic for healthcare providers. The recent recommendation by the US Preventive Services Task Force (USPSTF) against routine screening mammography for women 40-49 years old conflicts with recommendations made by other organizations such as the American Cancer Society and earlier recommendations made by the USPSTF in 2002. Click here to view the free full article.
Modestly elevated C-reactive protein (CRP) concentrations have been associated with an increased risk of coronary heart disease. The recently published and heavily publicized results of the JUPITER trial will…
Med Lett Drugs Ther. 2008 Dec 15; 50(1301):97-8
Modestly elevated C-reactive protein (CRP) concentrations have been associated with an increased risk of coronary heart disease. The recently published and heavily publicized results of the JUPITER trial will lead many patients to ask health care professionals whether they should have a CRP test to see if they should be taking a statin.
Levocetirizine ( Xyzal - UCB/Sanofi-aventis), the active enantiomer of the second-generation H 1 -antihistamine cetirizine ( Zyrtec ), has been approved by the FDA for treatment of seasonal and perennial…
Med Lett Drugs Ther. 2007 Dec 3; 49(1275):97-9
Levocetirizine ( Xyzal - UCB/Sanofi-aventis), the active enantiomer of the second-generation H 1 -antihistamine cetirizine ( Zyrtec ), has been approved by the FDA for treatment of seasonal and perennial allergic rhinitis (SAR and PAR) and chronic idiopathic urticaria in adults and children 6 years of age and older. Cetirizine has been approved by the FDA for over-the-counter use and may also become available generically in the US. Levocetirizine has been available in Europe since 2001.
Rasagiline ( Azilect - Teva), a monoamine oxidase-type B (MAO-B) inhibitor, was recently approved by the FDA for once-daily oral treatment of Parkinson's disease (PD). It can be taken alone for treatment of…
Med Lett Drugs Ther. 2006 Dec 4; 48(1249):97-9
Rasagiline ( Azilect - Teva), a monoamine oxidase-type B (MAO-B) inhibitor, was recently approved by the FDA for once-daily oral treatment of Parkinson's disease (PD). It can be taken alone for treatment of early disease or with levodopa/carbidopa ( Sinemet , and others) for advanced disease. Selegiline ( Eldepryl , and others), the first MAO-B inhibitor marketed in the US, has been available since 1988; a new lower-dose disintegrating tablet (Zelapar) was recently approved.